Haematinic Deficiency and Macrocytosis in Middle-Aged and Older Adults

Abstract

ObjectiveTo assess the prevalence and determinants of haematinic deficiency (lack of B12 folate or iron) and macrocytosis in blood from a national population-based study of middle-aged and older adults.MethodsA cross-sectional study involving 1,207 adults aged ≥45 years, recruited from a sub-study of the Irish National Survey of Lifestyle Attitudes and Nutrition (SLÁN 2007). Participants completed a health and lifestyle questionnaire and a standard food frequency questionnaire. Non-fasting blood samples were obtained for measurement of full blood count and expert morphological assessment, serum ferritin, soluble transferrin receptor assay (sTfR), B12, folate and coeliac antibodies. Blood samples were also assayed for thyroid function (T4, TSH), liver function, aminotransferase (AST) and gamma-glutamyl transferase (GGT).ResultsThe overall prevalence (95% C.I.) of anaemia (Hb <13.5g/dl men and 11.3 g/dl women) was 4.6% (2.9%–6.4%) in men and 1.0% (0.2%–1.9%) in women. Iron deficiency (ferritin <17ng/ml men and <11ng/ml in women) was detected in 6.3% of participants (3.7% in males and 8.7% in females, p<0.001). Based on both low ferritin and raised sTfR (>21nmol/ml) only 2.3% were iron-deficient. 3.0% and 2.7% were found to have low levels of serum folate (<2.3ng/ml) and serum B12 (<120ng/l) respectively. Clinically significant macrocytosis (MCV>99fl) was detected in 8.4% of subjects. Strong, significant and independent associations with macrocytosis were observed for lower social status, current smoking status, moderate to heavy alcohol intake, elevated GGT levels, deficiency of folate and vitamin B12, hypothyroidism and coeliac disease. The population attributable fraction (PAF) for macrocytosis associated with elevated GGT (25.0%) and smoking (24.6%) was higher than for excess alcohol intake (6.3%), folate deficiency (10.5%) or vitamin B12 (3.4%).ConclusionsHaematinic deficiency and macrocytosis are common in middle-aged/older adults in Ireland. Macrocytosis is more likely to be attributable to an elevated GGT and smoking than vitamin B12 or folate deficiency.

Anemia in the Elderly in Northeastern Thailand: A Community-Based Study Investigating Prevalence, Contributing Factors, and Hematologic Features

“…It is notable that the anemias within this group were of mild severity, with an average Hb level of 10.9 g/dL for females and 12.1 g/dL for males (Table 3). The increased MCV and MCH values observed in this study are consistent with those in previous reports [29,32]. In contrast, a decreasing trend of circulating RBCs may reflect a lower rate of erythropoiesis in older age groups.…”

Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults

“…The commonest causes of iron deficiency in the general population are inadequate intake, poor absorption of iron and, in particular, menstruation [1,2,3,4,5]. This helps explain the increased daily iron requirement and higher deficiency rates in women versus men [5,6,7,8]. Supplementation with oral iron is well established to prevent and treat iron deficiency anaemia and symptomatic fatigue [5].…”

“…Supplementation with oral iron is well established to prevent and treat iron deficiency anaemia and symptomatic fatigue [5]. However, iron food fortification and oral iron supplements are frequently limited by poor absorption and poor tolerability [3,4,7,8]. …”

Active smoking and macrocytosis in the general population: Two population‐based cohort studies

“…Importantly, this association was independent of known causes of macrocytosis, including alcohol use. A few years ago, McNamee et al 5 and O'Reilly et al 6 reinvestigated the association between smoking as unrecognized cause of macrocytosis and showed that cigarette smoking was a significant risk factor for macrocytosis, independent of other known causes. Unfortunately, at present cigarette smoking is still not mentioned in textbooks and major guidelines, and clinicians are generally unaware of this association.…”

“…Several studies on the use of venetoclax as single agent in relapsed/ refractory AML (r/r AML) demonstrated clinical activity with tolerable and safe profile 3 ; furthermore the addition of venetoclax to decitabine or azacitidine seems to sensitize AML cells to these hypomethylating agents (HMAs), in particular for patients with IDH mutations. [4][5][6] Relapsed AML after allogeneic hematopoietic stem cell transplantation (HSCT) have poor prognosis despite numerous therapies…”